Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

West Pharmaceutical Services (NY: WST )

320.88 +9.22 (+2.96%)
Official Closing Price Updated: 7:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about West Pharmaceutical Services

< Previous 1 2 3 4 5 6 7 8 9 Next >
Cameco, Applied Digital, West Pharmaceutical And More On CNBC's 'Final Trades'
On CNBC's "Halftime Report Final Trades," Tim Seymour of Seymour Asset Management picked Cameco Corporation. 
Via Benzinga
Looking Into West Pharmaceutical Servs's Recent Short Interest
Via Benzinga
Peering Into West Pharmaceutical Servs's Recent Short Interest
Via Benzinga
Balancing Dividends and Fundamentals: The Case of NYSE:WST.
Analyzing WEST PHARMACEUTICAL SERVICES (NYSE:WST)'s Dividend Potential. 
Via Chartmill
West Pharmaceutical's Q3 Performance Shows Rising Demand For Syringes, Company Boosts Annual Forecast And Dividend
West Pharmaceutical Services reported Q3 adjusted EPS of $1.85, beating estimates, with $746.9 million in sales. Updated 2024 guidance reflects higher EPS and sales. 
Via Benzinga
UPS Posts Upbeat Q3 Results, Joins Tesla, Celestica, Pool, T-Mobile And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Earnings Outlook For West Pharmaceutical Servs
Via Benzinga
(WST) - Analyzing West Pharmaceutical Servs's Short Interest
Via Benzinga
Exploring NYSE:WST's dividend characteristics.
Exploring WEST PHARMACEUTICAL SERVICES (NYSE:WST)'s dividend characteristics. 
Via Chartmill
Build-A-Bear Workshop Posts Upbeat Earnings, Joins Affirm, Nutanix, Cooper Companies, Veeva Systems And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Is NYSE:WST a Good Fit for Dividend Investing?
Why WEST PHARMACEUTICAL SERVICES (NYSE:WST) qualifies as a good dividend investing stock. 
Via Chartmill
S&P 500, Nasdaq 100 Mark Seventh Straight Positive Session, Strongest Week Since October 2023: Friday's Top Movers
S&P 500 and Nasdaq 100 indices gain for seventh straight day, marking best weekly performance since October 2023 on positive economic data. SPY and QQQ close with modest daily gains while DIA has best... 
Via Benzinga
Topics Stocks
Exposures US Equities
Balancing Dividends and Fundamentals: The Case of NYSE:WST.
Why the dividend investor may take a look at WEST PHARMACEUTICAL SERVICES (NYSE:WST). 
Via Chartmill
Why NYSE:WST is a Top Pick for Dividend Investors.
Exploring WEST PHARMACEUTICAL SERVICES (NYSE:WST)'s dividend characteristics. 
Via Chartmill
How Is The Market Feeling About West Pharmaceutical Servs?
Via Benzinga
Ford, Stellantis And Dell Are Among Top 12 Large Cap Losers Last Week (July 21-July 27): Are The Others In Your Portfolio?
Top 10 worst performers last week: EW (-28.05%), F (-19.12%), STM (-17.60%), TER (-16.25%), MBLY (-14.61%), STLA (-13.07%), VRT (-12.04%), SMCI (-11.68%), WST (-11.37%), DELL (-11.26%), UPS (-10.96%),... 
Via Benzinga
Why Edwards Lifesciences Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Uncovering Dividend Opportunities with NYSE:WST.
Why WEST PHARMACEUTICAL SERVICES (NYSE:WST) qualifies as a good dividend investing stock. 
Via Chartmill
Peering Into West Pharmaceutical Servs's Recent Short Interest
Via Benzinga
WST Stock Earnings: West Pharmaceutical Servs Misses EPS, Misses Revenue for Q2 2024
WST stock results show that West Pharmaceutical Servs missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
How Is The Market Feeling About West Pharmaceutical Servs?
Via Benzinga
WST Stock Earnings: West Pharmaceutical Servs Beats EPS, Beats Revenue for Q1 2024
WST stock results show that West Pharmaceutical Servs beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Why the dividend investor may take a look at NYSE:WST.
Via Chartmill
(WST) - Analyzing West Pharmaceutical Servs's Short Interest
Via Benzinga
Exploring NYSE:WST's dividend characteristics.
Why WEST PHARMACEUTICAL SERVICES (NYSE:WST) is a Top Pick for Dividend Investors. 
Via Chartmill
3 Pharma Stocks to Sell in March Before They Crash & Burn
Discover top pharma stocks to sell in March before they plummet. Learn why ACAD, AMLX and WST are on the list for urgent sell-off decisions. 
Via InvestorPlace
Analyzing NYSE:WST's Dividend Potential.
Is WEST PHARMACEUTICAL SERVICES (NYSE:WST) a Good Fit for Dividend Investing? 
Via Chartmill
S&P Reclaims 5,000 As Disappointing Retail Sales Put Fed Cuts Back On Track, Small Caps Shine: What's Driving Markets Thursday?
US stocks surge on strong earnings and speculation of Fed rate cuts. S&P 500 rebounds past 5000, Nasdaq 100 pauses. Small caps outperform. Tesla, Wells Fargo, and CBRE rally on positive news while Deer... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
West Pharmaceutical's 2024 Outlook Cautious, Analysts Remain Optimistic
West Pharmaceutical Services reports Q4 2023 adjusted EPS at $1.83, surpassing consensus. Quarterly sales hit $732 million missing estimates. 2024 guidance hints at moderated organic growth,... 
Via Benzinga
Why Herbalife Shares Are Trading Lower By Around 36%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Herbalife Ltd. (NYSE: HLF) fell sharply in today’s session following weak quarterly earnings. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.